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Edited by Hans-Dieter KlenkDedicated to the memory of Professor Vassilis GalanopoulosAbstract Although the hepatitis C virus (HCV) is an enveloped
virus, naked nucleocapsids have been reported in the serum of in-
fected patients, and most recently novel HCV subgenomes with
deletions of the envelope proteins have been identiﬁed. However
the signiﬁcance of these ﬁndings remains unclear. In this study,
we used the baculovirus expression system to generate recombi-
nant HCV capsid-like particles, and investigated their possible
interactions with cells. We show that expression of HCV core
in insect cells can suﬃciently direct the formation of capsid-like
particles in the absence of the HCV envelope glycoproteins and
of the 5 0 untranslated region. By confocal microscopy analysis,
we provide evidence that the naked capsid-like particles could
be uptaken by human hepatoma cells. Moreover, our ﬁndings
suggest that they have the potential to produce cell-signaling
eﬀects.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Hepatitis C virus (HCV) [1] is a major cause of liver disease
worldwide [2]. The majority of individuals infected by HCV
fail to resolve the infection, which progresses to chronicity,
often leading to ﬁbrosis, cirrhosis or hepatocellular carcinoma
(HCC) [3].
HCV is a single stranded, positive-sense RNA virus that be-
longs to the family Flaviviridae [4]. HCV is an enveloped virus;
the virion nucleocapsid is surrounded by a lipid bilayer contain-
ing the glycoproteinsE1 andE2.However,HCVmay exist in dif-
ferent forms in the circulation of infected individuals [5]. Among
the diﬀerent populations displaying heterogeneous buoyant
densities, the high-density particles are composed of naked viral
cores and/ or immune complexes [6,7]. Naked capsids have also
been reported in liver cells of infected patients [8].*Corresponding author. Fax: +30 210 6478877.
E-mail address: uraniag@mail.pasteur.gr (U. Georgopoulou).
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doi:10.1016/j.febslet.2007.07.032Neither the signiﬁcance of these non-enveloped capsids in
natural infection, nor the mechanism of their release into the
bloodstream of infected patients, is yet clear. However, it has
been suggested that the dominant HCV population changes
from low-density to high-density particles with the progression
of liver disease and inﬂammation [5]. Moreover patients with a
high ratio of low-density particles may respond to therapy bet-
ter than those with a high ratio of high-density particles [9].
More recently, novel HCV subgenomes were identiﬁed in the
liver as well as in the serum of HCV-infected individuals [10].
Notably the majority of these subgenomes had in-frame dele-
tions of both envelope proteins, and in one case the subgenome
was found to persist through the 2-year period of the study.
Another study suggested that circulating defective HCV clones
might be associated with poor response to combination therapy
[11]. These observations raise the question whether non-
enveloped capsids and/or E1/E2-defective genomes have
properties that might be associated with HCV pathogenesis
and persistence.
In the present study, we describe the use of the baculovirus
system for the expression and assembly of the HCV core pro-
tein, in the absence of the HCV envelope proteins. We also
investigate possible interactions of the recombinant naked cap-
sid-like particles with cells.2. Materials and methods
2.1. Plasmids
The HCV genotype 1a (H) cDNA [12] was used to generate the plas-
mid constructs used in this study.
For bacterial expression of the HCV core protein with an N-termi-
nal histidine-tag, the full-length (C191) core coding sequence (Fig. 1A)
was cloned into the pET15b plasmid (Novagen). Initially, the core
sequence was ampliﬁed by PCR with primers containing NdeI sites
and a stop codon, followed by direct cloning into the HincII site of
the pUC19 plasmid (New England Biolabs). Subsequently, the NdeI
fragment containing the core coding sequence was transferred to the
NdeI site of the pET15b, yielding pHPI 1319 (Fig. 1B).
For generation of a recombinant baculovirus expressing the HCV
core protein under the polyhedrin promoter (Bac1432), the C191
coding region was cloned into the EcoRI site of pBacPAK8 (Clontech)
to yield plasmid pHPI 1432 (Fig. 1B). As a control virus (not express-
ing core protein), recombinant Bac1462 was used.blished by Elsevier B.V. All rights reserved.
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Fig. 1. Expression of the HCV 1a core protein in Sf9 cells infected with the Bac1432 recombinant baculovirus. (A) Schematic representation of the
HCV genome. (B) Plasmid constructs used for the expression of recombinant core protein in bacteria (pHPI 1319), and for the generation of
baculovirus Bac1432 expressing HCV core (pHPI 1432). UTR, untranslated region; C+1, alternative reading frame protein; SS, signal sequence;
T7lac, T7 promoter-lac operator; pPH, polyhedrin promoter. (C) Coomassie brilliant blue (CBB) staining of lysates from mock-(lane 1), Bac1462
(control virus)-(lane 2) and Bac1432 (core virus)-(lane 3) infected insect cells. The band corresponding to the HCV core is indicated by an arrowhead.
(D) Time-course expression of core. Bac1432-infected Sf9 cells were harvested at indicated time-points p.i. (lanes 3–6), and lysates were analyzed by
immunoblotting with the polyclonal anti-core antibody (lane 1: mock; lane 2: Bac1462-infected cells). Infection of Sf9 cells was also performed in the
absence of fetal calf serum in the culture medium, and cells were harvested and analyzed as before (lane 7: mock; lanes 8–9: Bac1432). Arrowheads
indicate the two main forms of core protein. (E) Release of core protein into the supernatant. Culture medium from Bac1432-infected cells was
harvested at indicated time-points and analyzed by HCV core antigen ELISA (bars: dilution · signal-to-cutoﬀ ratio). Results shown are means of
duplicate wells ± standard deviation. Inset shows western blotting of ultracentrifuged supernatant collected at 48 h (lane 1: Bac1462; lane 2:
Bac1432).
4050 P. Tsitoura et al. / FEBS Letters 581 (2007) 4049–4057TheGFP-ERF plasmid [13] was used for transient expression of ERF,
and transfection of WRL68, Huh7 and BHK21 cells was performed as
previously described [14] or with jetPei (Poluplus-transfection). A
minimum of 100 transfected cells were counted for each condition
and 50 cells for each fraction quantity, in at least two independent wells.
2.2. Preparation of polyclonal antibody against HCV core protein
Recombinant HCV core protein was expressed and puriﬁed for the
generation of the speciﬁc rabbit polyclonal antibody used in the present
study. For this purpose, Escherichia coli BL21(DE3) cells were trans-
formed with the pHPI 1319 construct (Fig. 1B), and were subsequentlygrown and induced for protein expression with 1 mM (ﬁnal concentra-
tion) of isopropyl-b-D-thiogalactopyranoside (IPTG) (Fermentas). Cells
were harvested 4 h later.
Puriﬁcation of the his-tagged core protein was performed by aﬃnity
chromatography on a nickel–nitrilotriacetic acid (Ni–NTA) agarose
(Qiagen) column under native conditions, according to the manufac-
turer’s protocol. Elutionwas performedwith 250 mMimidazole (Sigma).
Protein purity was assessed by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS–PAGE) and conﬁrmed by Western immuno-
blot analysis using speciﬁc monoclonal antibody against HCV core.
Protein concentration was determined by the Bio-Rad protein assay.
P. Tsitoura et al. / FEBS Letters 581 (2007) 4049–4057 4051A rabbit was subcutaneously immunized with four injections of the
puriﬁed HCV core protein. The hyperimmune serum was screened by
western blot and was found to react speciﬁcally with the HCV core pro-
tein. It was used thereafter in immunoblotting at 1:100–1:500 dilutions.
For immunoﬂuorescence and indirect immunogold electron micro-
scopy, the polyclonal anti-HCV core antibody was further puriﬁed
by aﬃnity chromatography, using the recombinant core protein cou-
pled to cyanogen bromide-activated-Sepharose 4B (Sigma) resin.
Recovery and purity of the puriﬁed antibody were determined by
absorbance at 280 nm and SDS–PAGE, while activity of the eluted
antibodies was veriﬁed by western blot.
2.3. Construction of recombinant baculoviruses
The Spodoptera frugiperda Sf9 cell line was used for the generation
and propagation of recombinant baculoviruses Bac1432 and
Bac1462. Cells were maintained in Sf900II SFM (Gibco) medium sup-
plemented with 5% fetal bovine serum at 27 C.
Generation of recombinant baculoviruses was performed according
to standard protocols using Baculogold linearized DNA (BD Biosci-
ences), and propagation of viruses was performed in 5% Sf900 medium
supplemented with 50 lg/ml gentamicin (Gibco).
2.4. SDS–PAGE and immunoblotting analysis
Time-course expression of HCV core in Sf9 cells infected by the re-
combinant baculovirus Bac1432 (or Bac1462 as a negative control) was
analyzed by immunoblotting with the polyclonal anti-core antibody.
Cells grown in 6-well plates were infected at a multiplicity-of-infection
(MOI) of 7 and harvested at diﬀerent time-points post-infection
(p.i.). A small aliquot (1/20) of the lysates was subjected to 12% or
13% SDS–polyacrylamide gel electrophoresis followed by electroblot-
ting to nitrocellulose membrane (Schleicher and Schuell). Membranes
were stained with Ponceau S (Sigma) and blocked with 5% non-fat dry
milk in phosphate-buﬀered saline (PBS), 0.01% Tween 20 (Sigma) for
1 h, before the addition of the primary antibody. The blots were then
probed with horseradish peroxidase-conjugated goat anti-rabbit
immunoglobulins (Chemicon) and were ﬁnally visualized with the
ChemiLucent detection system (Chemicon).
Proteins were also visualized by Coomassie brilliant blue (Sigma)
staining.
2.5. Detection of HCV core in the supernatant
Release of core protein into the supernatant was assessed by the use
of the Ortho Antibody to HCV core antigen ELISA test system
(Ortho-Clinical Diagnostics). The assay was performed with aliquots
of supernatant from cells grown in 12-well plates, either directly used
(100 ll) or after diluting 1:4. For immunoblot analysis, serum-free
supernatant from Bac1432-infected cells (2 · 107) was collected at
48 h p.i. and concentrated through a 30% sucrose cushion for 3 h at
29,000 rpm (SW41 Beckman rotor). An aliquot (1/12) of the resus-
pended pellet was subjected to SDS–PAGE.
2.6. Sucrose density gradient analysis
Sf9 cells (approximately 4 · 107) were infected with Bac1432 at an
MOI of 5 and harvested at 2 days p.i. The capsid-like particles were
isolated from cell lysates, according to the procedure described by
Baumert [15] or in [16]. Brieﬂy, the cleared cell lysate was directly
layered onto a discontinuous 20–59% w/w sucrose gradient (in
50 mM Tris–100 mM NaCl). Ultracentrifugation was carried out at
35,000 rpm for 22 h (SW41 Beckman rotor).
Fifteen fractions (700 ll each) were collected from the top of the gradi-
ent, checked for density by refractometry, and analyzed both by the
Ortho HCV core antigen ELISA test system (100 ll at a dilution
1:5,000 inPBS), andbySDS–PAGE(20 ll) followedby immunoblotting.
Total protein concentrations were measured by the Bio-Rad protein as-
say (1:100 dilution). The fractions were stored at80 C. Same fraction-
ation procedure was followed for lysates infected with a control virus.
2.7. Visualization of recombinant capsids by immunoﬂuorescence
microscopy
Immunoﬂuorescence microscopy was used to analyze the presence of
the putative HCV capsids, to estimate their diameter and to conﬁrm
their antigenic nature. As a standard for calibration, we used red ﬂuo-
rescent microspheres, 0.1 lm in diameter (from Molecular Probes).A mixture of core-positive fraction (2 ll) and of properly diluted
microspheres (5 ll) was spread and air-dried on a glass slide, and pro-
cessed for immunostaining as described before [17]. Brieﬂy, after ﬁxa-
tion and permeabilization, the sample was incubated with the
polyclonal anti-core antibody (1:100), followed by incubation with
the anti-rabbit Alexa Fluor 488-conjugated secondary antibody
(Molecular Probes) diluted 1:1000. After mounting, the slides were ob-
served by confocal microscopy.
2.8. Electron microscopy
Sucrose gradient fractions (10–13) positive for HCV core were
pooled and dialyzed in PBS to remove sucrose. A drop of the sample
(or a mixture with microspheres) was applied to the grid for 1–2 min,
and negatively stained with phosphotungstic acid or uranyl acetate.
For immune electron microscopy (IEM), the sample was applied to
the grid for 10 min and was probed with the polyclonal anti-core anti-
body (diluted 1:50 in 1% BSA-PBS) for 1 h, followed by incubation
with goat anti-rabbit antibody conjugated with gold particles (British
Biocell Int.), diluted 1:40 in 0.2% BSA-PBS. After washes (the last
one with water), the grid was negatively stained with 2% aqueous ura-
nyl acetate for observing by electron microscopy.
2.9. Analysis of cellular binding and entry
Huh7 cells were maintained in Dulbecco’s MEM (Biochrom AG)
containing 10% fetal calf serum. To study uptake, cells grown on
coverslips in 12-well plates were incubated with 15–50 ll (from approxi-
mately 10 ng/ll core protein) of puriﬁed HCV capsid-like particles
(peak fractions). Incubation was performed at 4 C or room tempera-
ture (RT), in 300 ll of DMEM for 30–45 min. In some experiments,
cells were further incubated for an additional 20 min at 37 C. Heat-
denatured (20 min at 90 C) core-fraction and control preparation
(from the corresponding fraction of control virus-infected cells) were
used as negative controls. Uptake was analyzed by indirect immunoﬂu-
orescence with the polyclonal anti-core antibody. Brieﬂy, after removal
of non-bound material, cells were ﬁxed with 3.7% paraformaldehyde
for 30 min at RT and neutralized with 100 mM glycine. Incubation
with the anti-core antibody was at a dilution of 1:100 for 40 min, fol-
lowed by anti-rabbit Alexa Fluor 488-conjugated secondary antibody
(Molecular Probes) diluted 1:1,000 for 40 min. Permeabilization was
carried out with 0.05% saponin or with 0.05–0.1%TX100.
To examine the eﬀect of anti-core antibody, cells were coincubated
at RT with the core- (or the control) fraction and 5–10 ll (from
0.65 lg/ll) of the polyclonal antibody. Immunoﬂuorescence analysis
was as above, except that in one slide, incubation with the primary
antibody was omitted.
Slides were examined with a Leica TCS-SP confocal microscope.3. Results
3.1. Expression of the HCV core protein in insect cells by a
recombinant baculovirus
The baculovirus Bac1432 was generated as described in Sec-
tion 2, and expression of the HCV core protein in infected cells
was examined initially at 48 h p.i. by SDS–PAGE, followed by
staining with Coomassie brilliant blue. As shown in Fig. 1C, a
band of approximately 21 kDa was present only in lysates
from Bac1432-infected, but not in lysates from mock- or
Bac1462 (the control recombinant virus)-infected cells, sug-
gesting that the core protein was eﬃciently expressed.
Time-course expression of HCV core was subsequently ana-
lyzed by immunoblotting analysis using the speciﬁc polyclonal
anti-core antibody prepared in this study (see Section 2). As
shown in Fig. 1D (lanes 1–6), western blot revealed two pre-
dominant bands of approximately 23 and 21 kDa, most prob-
ably representing the two forms of core (the lower band being
the mature form after removal of the E1 signal sequence)
[18,19]. Some less intense bands of lower molecular weight
could also be visualized, probably representing degradation
4052 P. Tsitoura et al. / FEBS Letters 581 (2007) 4049–4057products of core due to its overexpression. Expression of core
appeared to reach maximum levels between 48 and 72 h post-
infection. Infection was also performed in the absence of fetal
calf serum in the cell culture medium, and expression of the
HCV core protein was still very eﬃcient (Fig. 1D, lanes 7–9).
Next, we investigated if core could be released into the
culture medium. Supernatants from cells infected by the
Bac1432 virus were collected at indicated hours post-infection
and analyzed by a qualitative HCV core ELISA. As shown in
Fig. 1E, core could ﬁrst be detected in the supernatant at 24 h
p.i., albeit in very low amounts. Release continues to increase
progressively. Supernatant was also concentrated by ultracen-
trifugation and analyzed by western blotting (Fig. 1E, inset).
The presence of HCV core in the pellet of ultracentrifuged
supernatant suggests that HCV core detected in the culture
supernatant might be in particulate or insoluble form.
To determine if cell lysis could account for the release of core
in the supernatant, a cytotoxicity assay based on lactate dehy-
drogenase (LDH) was performed in the cell culture superna-
tants, which showed that signiﬁcant cell lysis occurred at
72 h p.i. (data not shown).
These results show that the HCV core protein is released
into the culture supernatant albeit with low eﬃciency.
3.2. Assembly of the HCV core protein
We next examined whether the core protein expressed in
insect cells by the Bac1432 virus could self-assemble, in the ab-
sence of additional HCV structural proteins, into capsids that
could be puriﬁed by sucrose density centrifugation. To this
end, infected cell lysates were fractionated, as described in Sec-
tion 2, and gradient fractions were collected and analyzed for
the presence of core protein by the use of the HCV core antigen
ELISA (Fig. 2A). The density of fractions demonstrating sig-
niﬁcant immunoreactivity for core was 1.17–1.24 g/cm3. This
range of densities is in good agreement with the density of
serum-derived nucleocapsids [5,20–23], of recombinant capsids
produced with other systems [24,25], or with the density
reported for capsids produced from enveloped virus-like parti-
cles after removal of the envelope with detergent [26]. FractionsFig. 2. Sucrose density gradient analysis of Sf9 cell lysates infected with the
sample) were analyzed by HCV core antigen ELISA (bars: S/CO). Rhombuses
concentration. Insets show staining and the immunoblot analysis of fra
Visualization of capsid-like particles after immunoﬂuorescent staining of cor
calibration; c: overlay; inset: detail of a single microsphere and particle). Bar:
staining; c: immunolabeling with anti-core antibody; insets: detail of single mwere also analyzed by SDS–PAGE and immunoblotting with
the anti-core antibody (inset), as well as for total protein, show-
ing that the core-positive fractions are quite enriched in HCV
core.
As immunoﬂuorescent staining of single particles has been
reported [17], we used this technique as an alternative method
to visualize the particles, to estimate the diameter of the puri-
ﬁed structures and to conﬁrm their antigenic nature. As shown
in Fig. 2B, individual red and green spots could be identiﬁed in
the fraction–microsphere mixture. The red spots correspond to
the ﬂuorescent microspheres, which were used as a standard,
while the green spots correspond to the structures puriﬁed by
the sucrose gradient and which were labeled with the anti-core
antibody. The speciﬁcity of staining was demonstrated by
using a mixture of microspheres and the control fraction; no
structures were detected except for the microspheres (not
shown). The size of the immunostained complexes is approxi-
mately from half to two-thirds of the 100 nm microspheres,
consistent with the size of non-enveloped capsids as reported
by others [7,26,27].
Electron microscopy of core-positive fractions after dialysis
and negative staining revealed the presence of almost uniform
spherical structures (Fig. 2Ca,b) of smaller size than the micro-
spheres (insets of Fig. 2Cb). Immunogold labeling (Fig. 2Cc)
revealed the presence of core- speciﬁc antigenic epitopes.
3.3. Uptake by cells
To examine whether recombinant capsid-like particles could
bind and enter into cells, core-positive fractions were added to
Huh7 cells. Adsorption was performed at 4 C or at room tem-
perature for 30 min, and binding and entry were visualized by
indirect immunoﬂuorescence microscopy using the anti-core
polyclonal antibody. As shown by the presence of ﬂuorescent
spots in Fig. 3A and B, binding occurred with adsorption per-
formed either at 4 C or at room temperature. As expected, no
binding was observed when control fraction-preparation
(Fig. 3C) was used. Moreover, heat-denaturation (Fig. 3D)
of the core-fraction resulted in a diﬀerent pattern of staining,
suggesting that the ﬂuorescent signal was speciﬁc to the coreBac1432 recombinant baculovirus. (A) Gradient fractions (every other
indicate the buoyant density of each fraction. Rectangles, total protein
ctions (respective numbers) with polyclonal anti-core antibody. (B)
e-positive fractions (a: core-positive fraction; b: microspheres used for
2 lm. (C) Electron microscopy of core-positive fractions (a,b: negative
icrospheres and particles). Bar: 50 nm.
Fig. 3. Analysis of cellular uptake of capsid-like particles by immunoﬂuorescence. Huh7 cells were incubated for 30 min with the core-fraction at
4 C (A) and at RT (B), or, as a negative control, with the control preparation (C) and the heat-denatured core-fraction (D). Cells were ﬁxed and
stained with the anti-core antibody. Shown are individual confocal sections.
P. Tsitoura et al. / FEBS Letters 581 (2007) 4049–4057 4053particle-containing fraction. Fluorescent spots were also ob-
served inside the cytoplasm (Fig. 5A) suggesting that entry
can occur.
In order to test if the interaction of the capsid-like particles
with the cells has the potential to create a cell signaling eﬀect,
we transfected WRL68, Huh7 and BHK21 (not shown) cells
with the GFP-ERF plasmid, followed by incubation with the
core-positive and the corresponding negative control fractions
(Fig. 4). ERF is a very sensitive and constant sensor of ERK
activity providing a link between the Ras/ERK pathway and
cellular proliferation [13]. In serum starved-transfected
WRL68 and Huh7 cells, incubation with the core-positive frac-
tion showed translocation of ERF from the nucleus resulting
almost in a cytoplasmic distribution of ERF (Fig. 4A1 and
B1), similar to starved cells treated with 30% serum
(Fig. 4A3 and B3). In contrast, incubation with the control
fraction showed nuclear distribution of the indicator
(Fig. 4A2 and B2) similar to the starved cells (Fig. 4A4 and
B4).In order to investigate if this eﬀect is dose-dependent,
the GFP-ERF transfected WRL68 and Huh7 cell lines were
incubated with various amounts of core-positive fraction,
ranging from 0 to 30 ng of core protein. The results
(Fig. 4C) show that the core-positive fraction has the capacity
to induce a dose-dependent, cell-signaling eﬀect related to
ERK, when exogenously added to the cell.
We next assessed if binding and/or entry can be blocked by a
speciﬁc anti-core antibody. For this purpose, cells were coincu-
bated with the core-positive fraction and the polyclonal anti-
body, and immunoﬂuorescence analysis was carried out.
Surprisingly, confocal microscopy showed (Fig. 5) that the
anti-core polyclonal antibody not only was unable to inhibit
the cellular uptake, but on the contrary the signal was repeat-
edly more intense, as compared to that without incubation
with the antibody (compare Fig. 5A and B). This enhancement
was not observed when we used non-relevant rabbit IgG (data
not shown). Moreover, the capsid-like particles appeared to be
internalized by the cells (Fig. 5A and B), as the characteristic
punctuate ﬂuorescent staining was not limited to the cell mem-
brane but was also evident in the cytoplasm.
This enhanced signal could be due to enhanced uptake of
capsid-like particles in the presence of the anti-core antibody.
Alternatively, if core could enter the cells as an immune com-
plex with the anti-core antibody, this intense signal could be
explained by simultaneous detection of the speciﬁc antibody(being internalized), when the standard indirect immunoﬂuo-
rescence protocol was followed. To address this question, we
performed another set of experiments. Cells were incubated
with both the core-fraction and the speciﬁc antibody, and
staining was performed either as before, with the anti-core
antibody (Fig. 5D), or with the secondary anti-rabbit antibody
alone (i.e. the anti-core antibody was omitted, Fig. 5E). This
would allow us to assess whether the anti-core antibody was
internalized in the presence of the core-fraction. Immunoﬂuo-
rescence microscopy revealed the presence of ﬂuorescent spots
corresponding to the anti-core antibody (Fig. 5E). This uptake
could take place only upon simultaneous adsorption of core-
fraction, as the incubation of the antibody with the corre-
sponding control preparation did not result in any detectable
staining (Fig. 5C). These results suggest that the core and the
antibody may enter into cells as an immune complex.4. Discussion
Previous observations have suggested that nucleocapsids
without a lipid envelope circulate in the serum of HCV-
infected patients. However little is known about the nature,
the origin and the properties of these naked particles. This is
the ﬁrst report showing that recombinant non-enveloped
HCV capsids are competent for binding and entry to cells.
The biological signiﬁcance of this phenomenon remains
unclear, since it is not currently known if naturally occurring
naked particles can indeed be infectious. Recently, defective
HCV genomes lacking envelope-coding sequences have been
identiﬁed to be predominant in several patients [10,11,28]. It
is tempting to speculate that non-enveloped capsids might be
produced under certain circumstances, containing either the
defective or the full-length genome. However in vitro results
do not support the hypothesis that E1/E2-defective genomes
can produce infectious particles, although they can autono-
mously replicate [29,30].
Alternatively, even in the case that circulating non-enveloped
particles are empty or non-infectious, another possibility is that
their binding and/or entry to the cells could interfere with sig-
naling pathways of the host, and therefore might be associated
with some of the immunopathological eﬀects of HCV infection.
From our results we have indication that binding of naked core
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4054 P. Tsitoura et al. / FEBS Letters 581 (2007) 4049–4057particles can modulate the Ras/ERK signaling pathway. It
is interesting to note that aside from its role in the nucleocap-
sid formation, HCV core has been shown to be a multifunc-
tional protein and to aﬀect many host cell functions [31,32],
such as lipid metabolism, apoptosis, gene transcription and
signaling pathways. Furthermore, core has been associated
with the induction of steatosis and HCC, and may also have
an immunoregulatory role. These observations suggest that
HCV core by itself may be one causative agent of liver cell
injury, and therefore core particles circulating in the serum of
HCV-infected patients might not be inert. In this context, it is
interesting to note that sera from hepatitis B patients have been
shown to contain empty, non-infectious particles [33].
Another interesting result of this study was the indication
that the capsid-like particles and the antibody may enter thecells as an immune complex. Again the physiological relevance
of this phenomenon is unclear. As known, besides the common
receptor/coreceptor-dependent mechanism of cellular attach-
ment, some viruses rely on antiviral or non-neutralizing
antibodies for their eﬃcient entry into target cells. Antibody-
dependent enhancement of viral infection was originally
described for some members of the Flaviviridae family [34,
reviewed in]. It is tempting to speculate that upon binding to
the non-enveloped particle, the anti-core antibody might
induce a conformational change or involvement of speciﬁc
Fc/complement receptors. This could be an unconventional
means by which not only hepatocytes, but also other cells,
including cells of the immune system, could internalize the core
particles. In this context, it is of interest to note that immune
complexes have been shown to exist in HCV [6], and one study
Fig. 5. Uptake of capsid-like particles in the presence of the polyclonal anti-core antibody. Huh7 cells were incubated for 30 min at RT with the core-
fraction (A), or with both the core-fraction and the anti-core antibody (B). Cells were ﬁxed, stained with anti-core and examined by
immunoﬂuorescence microscopy. To examine if uptake of anti-core antibody takes place, cells were incubated with both the anti-core antibody and
either the control (C) or the core (D,E) fraction. For panels C and D, immunoﬂuorescence analysis was carried out as normal, while in panel E the
primary antibody incubation was omitted. Shown are individual confocal sections.
P. Tsitoura et al. / FEBS Letters 581 (2007) 4049–4057 4055suggested that some of these immune complexes may contain
non-enveloped core antigen [35]. Recently, interaction of
immune complexes isolated from HCV-infected individuals
with monocytic and lymphocytic cell lines [36], and cryoglob-
ulin-associated uptake of HCV into human hepatocytes [37]
were shown; however the latter observations might rather be
related to complete virions.
On the other hand, it is interesting that a similar phenome-
non was reported for another hepatitis virus: binding and up-
take of hepatitis A virus–anti-HAV IgA immunocomplexes
into hepatocytes, which may play a role in relapsing HAV
infections [38].
To generate the recombinant naked capsids, we used the bac-
ulovirus expression system. This system has been used widely
for the production of enveloped HCV-like particles [15,39–
44], as the lack of a cell culture system allowing for the robust
propagation of HCV has long hampered the study of some
aspects of the HCV lifecycle (such as the entry, assembly and
egress). However, limited work exists regarding the use of
this system for the expression and assembly of the HCV core
protein in the absence of other HCV structural proteins, and
results are variable regarding the use of this system for the
production of recombinant HCV naked particles. Firstly,
Wang et al. [45] have generated baculoviruses expressinghistidine-tagged 1b core protein, but could not detect the
formation of any core-like particles. Subsequently Choi [46]
reported the presence of core-like particles only in the superna-
tant and not intracellularly. In the present study we show that
expression of HCV core is very eﬃcient in insect cells, and that
it can suﬃciently direct the formation of capsid-like particles,
which were puriﬁed from cell lysates. Moreover, in accordance
with other studies [46], the core protein, in the absence of other
HCV proteins, could be detected in the supernatant of insect
cells. It is interesting to note that HCV structural proteins
and/or VLPs could not be detected in the supernatant of insect
cells expressing the entire HCV structural region [7,15].
The 5 0 UTR of HCV was not included in the construct used
in the current study, as it has been shown to prevent transla-
tion in insect cells [45]. However we were able to observe cap-
sid assembly, in agreement with the results concerning the
assembly of enveloped virus-like particles [15,39–44], which
was shown with constructs lacking part or all of the 5 0 untrans-
lated region. It should be noted that several reports describe
the assembly of capsids of other viruses through the use of re-
combinant baculoviruses expressing one or more capsid pro-
teins [47–52]. It is possible that these recombinant capsids
could be empty, or that they could contain cellular RNA tran-
scripts or the speciﬁc transcript.
4056 P. Tsitoura et al. / FEBS Letters 581 (2007) 4049–4057Although other systems have been used as well to study
assembly of the HCV core protein [24,25,27,53–56], the bacu-
lovirus expression system described here allows for the study of
capsid assembly in a versatile, cell-based system and for the
partial puriﬁcation of the derived naked capsid-like particles
in suﬃcient quantities, which might be useful for potential
applications ranging from basic virological studies to develop-
ments in biomedicine.
In summary, we have generated recombinant non-enveloped
HCV core particles in the absence of other HCV proteins by
using the baculovirus system. More importantly, we have found
that these naked capsids can be uptaken by cells, alone or as
immune-complexes with the speciﬁc core antibody, and can
induce cell-signaling phenomena. However, further elucidation
of the exact mechanism of entry and the consequent eﬀects on
the host cell will be necessary in order to understand the poten-
tial role of non-enveloped capsids in HCV pathogenesis.
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